Physician
Marietta Memorial Hospital
Marietta Memorial Hospital was paid $102.25M by Medicaid between Jan 2018 and Dec 2024, across 616 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 17% of everything it billed.
33Billing provider infoMARIETTA MEMORIAL HOSPITAL
MARIETTA, OH 45750
MARIETTA, OH 45750
33aNPI1215936927assigned 07/15/2005
33bProvider typeEmergency Medicine Physician
28Total paid$102.25M
24GClaims2,714,515
24DCodes billed616
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Ohio
Rank by total paid#1 of 368
Median peer was paid$13K
This provider vs. median7,931×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 265,316 | $12.78M | |
| 2019 | 238,931 | $9.97M | |
| 2020 | 248,353 | $12.89M | |
| 2021 | 302,981 | $10.09M | |
| 2022 | 404,671 | $13.77M | |
| 2023 | 717,511 | $24.27M | |
| 2024incomplete | 536,752 | $18.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 278,497 | 192,506 | $17.78M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 70,898 | 58,563 | $14.01M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.0% | 128,824 | 94,154 | $9.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.6% | 63,105 | 55,440 | $6.77M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.1% | 148,354 | 127,743 | $6.24M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.3% | 54,299 | 49,067 | $5.44M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 14,566 | 9,935 | $2.44M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 10,793 | 9,060 | $2.40M |
| 80053 | Comprehensive metabolic panel | 1.2% | 86,823 | 73,750 | $1.25M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 6,101 | 5,265 | $1.04M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,983 | 5,952 | $1.02M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 13,824 | 7,262 | $979K |
604 more codes
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 12,842 | $972K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,521 | $898K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,334 | $709K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,071 | $698K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,755 | $676K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 91,559 | $657K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 29,369 | $643K |
| 76830 | Ultrasound, transvaginal | <1% | 5,705 | $508K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,429 | $505K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,925 | $500K |
| 64483 | <1% | 1,383 | $490K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,585 | $462K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,510 | $448K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 4,842 | $436K |
| G0378 | Hospital observation service, per hour | <1% | 6,726 | $434K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 4,690 | $431K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,992 | $430K |
| 36415 | Collection of venous blood by venipuncture | <1% | 126,823 | $428K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,827 | $427K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,140 | $425K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 5,407 | $408K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,161 | $407K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,045 | $402K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 10,184 | $394K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,220 | $376K |
| 20610 | <1% | 2,351 | $373K | |
| 20553 | <1% | 4,220 | $373K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24,086 | $348K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,489 | $325K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 25,256 | $307K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,647 | $305K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 7,340 | $304K |
| 95886 | <1% | 2,951 | $304K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,387 | $298K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,727 | $294K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,000 | $271K |
| 81001 | <1% | 41,320 | $261K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,342 | $255K |
| 72131 | <1% | 2,488 | $252K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,839 | $250K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 313 | $241K |
| 98929 | <1% | 11,024 | $239K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,701 | $235K |
| 27096 | <1% | 812 | $234K | |
| 59025 | Fetal non-stress test | <1% | 1,602 | $232K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,899 | $229K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,116 | $226K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,862 | $219K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,706 | $218K |
| 80061 | Lipid panel | <1% | 17,967 | $210K |
| 85027 | <1% | 27,207 | $206K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,521 | $194K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,485 | $189K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 380 | $178K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,992 | $178K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,226 | $177K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,052 | $175K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,090 | $173K |
| J3490 | Unclassified drugs | <1% | 8,126 | $171K |
| 96376 | <1% | 5,908 | $165K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,056 | $164K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,134 | $164K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,819 | $163K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,383 | $161K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 460 | $160K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,703 | $155K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 719 | $154K |
| 97161 | <1% | 2,712 | $147K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,583 | $142K |
| 84439 | <1% | 9,150 | $142K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,787 | $141K |
| 70496 | <1% | 552 | $140K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,433 | $131K |
| 83690 | <1% | 15,396 | $131K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,467 | $128K |
| 84484 | <1% | 16,473 | $126K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,160 | $124K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 210 | $122K |
| 82962 | <1% | 20,169 | $121K | |
| 72141 | <1% | 602 | $120K | |
| 95811 | <1% | 290 | $120K | |
| 73630 | <1% | 4,347 | $118K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,328 | $117K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 662 | $110K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 218 | $108K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,815 | $107K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,335 | $104K |
| 64493 | <1% | 270 | $104K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,940 | $102K |
| 81025 | <1% | 7,956 | $98K | |
| 82607 | <1% | 6,540 | $98K | |
| 74018 | <1% | 2,534 | $98K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,775 | $95K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,323 | $90K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,476 | $90K |
| 93971 | <1% | 1,219 | $88K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,053 | $87K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,752 | $87K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,526 | $87K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,380 | $87K |
| 83735 | <1% | 12,717 | $86K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 7,565 | $85K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,677 | $84K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 3,542 | $83K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,981 | $80K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,598 | $79K |
| 73610 | <1% | 2,805 | $79K | |
| 93017 | <1% | 1,044 | $78K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,917 | $78K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,530 | $77K |
| 87077 | <1% | 5,942 | $76K | |
| 84702 | <1% | 3,566 | $76K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,619 | $75K |
| 85610 | <1% | 9,893 | $75K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,326 | $73K |
| 71250 | <1% | 1,065 | $73K | |
| 73030 | <1% | 2,986 | $72K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,031 | $72K |
| 86850 | <1% | 2,576 | $71K | |
| 73130 | <1% | 2,375 | $70K | |
| 92551 | <1% | 3,264 | $70K | |
| 87631 | <1% | 311 | $69K | |
| 92557 | <1% | 785 | $68K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 472 | $68K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,494 | $67K |
| 92567 | <1% | 2,635 | $65K | |
| 86140 | <1% | 6,035 | $64K | |
| 76536 | <1% | 740 | $63K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 101 | $63K |
| 73564 | <1% | 1,977 | $62K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 5,336 | $61K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 710 | $61K |
| 87186 | <1% | 5,407 | $60K | |
| 99223 | Prolong inpt eval add15 m | <1% | 1,198 | $59K |
| 80076 | <1% | 4,705 | $57K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 81 | $56K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 401 | $56K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 3,109 | $56K |
| 86900 | <1% | 2,877 | $56K | |
| 64490 | <1% | 158 | $55K | |
| 83880 | <1% | 4,975 | $55K | |
| 72110 | <1% | 1,851 | $54K | |
| 64615 | <1% | 232 | $51K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,127 | $51K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,657 | $48K |
| 73110 | <1% | 1,671 | $48K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 8,835 | $47K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 291 | $47K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 318 | $47K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,593 | $46K |
| 85379 | <1% | 3,135 | $46K | |
| 70491 | <1% | 198 | $45K | |
| 83550 | <1% | 6,140 | $45K | |
| 83540 | <1% | 6,420 | $44K | |
| 88342 | <1% | 2,589 | $44K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 7,320 | $44K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,039 | $44K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 290 | $44K |
| 87040 | <1% | 3,919 | $43K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,757 | $43K |
| 85730 | <1% | 4,970 | $43K | |
| 76641 | <1% | 309 | $43K | |
| 84703 | <1% | 4,184 | $43K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,222 | $42K |
| 82553 | <1% | 2,345 | $42K | |
| 99406 | <1% | 4,253 | $42K | |
| 82550 | <1% | 3,659 | $41K | |
| 11721 | <1% | 3,801 | $41K | |
| 85007 | <1% | 5,980 | $41K | |
| 87070 | <1% | 2,400 | $41K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,620 | $41K |
| 90648 | <1% | 4,201 | $40K | |
| 17110 | <1% | 312 | $39K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 885 | $38K |
| 71271 | <1% | 228 | $38K | |
| 72128 | <1% | 874 | $37K | |
| 97165 | <1% | 855 | $36K | |
| 86780 | <1% | 2,983 | $36K | |
| 83605 | <1% | 5,546 | $35K | |
| 85652 | <1% | 6,093 | $35K | |
| 73221 | <1% | 225 | $35K | |
| 96367 | <1% | 1,939 | $35K | |
| 86901 | <1% | 2,870 | $34K | |
| 86703 | <1% | 2,225 | $34K | |
| 94726 | <1% | 1,342 | $33K | |
| 94010 | <1% | 1,040 | $33K | |
| 90670 | <1% | 4,240 | $33K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,812 | $33K |
| 87480 | <1% | 2,365 | $32K | |
| 82565 | <1% | 2,955 | $32K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,823 | $32K |
| 76642 | <1% | 263 | $31K | |
| 74178 | <1% | 164 | $30K | |
| 74420 | <1% | 367 | $30K | |
| 87660 | <1% | 2,282 | $29K | |
| 87510 | <1% | 2,344 | $29K | |
| 80074 | <1% | 1,545 | $28K | |
| 70486 | <1% | 422 | $28K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,834 | $27K |
| 90686 | <1% | 3,481 | $26K | |
| 73562 | <1% | 1,319 | $26K | |
| 94729 | <1% | 1,324 | $26K | |
| 72050 | <1% | 888 | $25K | |
| 36591 | <1% | 1,132 | $24K | |
| 82728 | <1% | 2,207 | $24K | |
| 88341 | <1% | 574 | $24K | |
| 00731 | <1% | 817 | $24K | |
| 12001 | <1% | 161 | $23K | |
| 84100 | <1% | 3,837 | $23K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 862 | $23K |
| 73502 | <1% | 1,299 | $22K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 371 | $22K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,105 | $22K |
| 72100 | <1% | 765 | $22K | |
| 82746 | <1% | 1,921 | $22K | |
| 88307 | <1% | 260 | $22K | |
| 70498 | <1% | 566 | $22K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 768 | $21K |
| 11102 | <1% | 52 | $21K | |
| 94618 | <1% | 512 | $20K | |
| 20550 | <1% | 104 | $20K | |
| 81513 | <1% | 134 | $19K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 439 | $19K |
| 88142 | <1% | 475 | $19K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 601 | $19K |
| 99349 | <1% | 315 | $19K | |
| 73560 | <1% | 1,115 | $19K | |
| 98928 | <1% | 997 | $19K | |
| 92587 | <1% | 180 | $18K | |
| 83970 | <1% | 769 | $18K | |
| 84481 | <1% | 1,322 | $17K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 125 | $17K |
| 97012 | <1% | 503 | $17K | |
| 83655 | <1% | 708 | $16K | |
| 86480 | <1% | 514 | $16K | |
| 84153 | <1% | 1,448 | $16K | |
| 90633 | <1% | 1,770 | $16K | |
| 84146 | <1% | 999 | $15K | |
| 73090 | <1% | 531 | $15K | |
| 87340 | <1% | 1,240 | $15K | |
| 73080 | <1% | 795 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 518 | $14K |
| 82977 | <1% | 1,739 | $14K | |
| 86038 | <1% | 869 | $14K | |
| 90723 | <1% | 2,767 | $14K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,354 | $13K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,682 | $13K |
| 86308 | <1% | 817 | $13K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 197 | $13K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 399 | $13K |
| 93880 | <1% | 194 | $13K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 14 | $13K |
| 96523 | <1% | 449 | $13K | |
| 69210 | <1% | 467 | $13K | |
| 77065 | Tomosynthesis, mammo | <1% | 350 | $13K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,375 | $13K |
| 72072 | <1% | 360 | $13K | |
| 88304 | <1% | 732 | $12K | |
| 74246 | <1% | 100 | $12K | |
| 82570 | <1% | 1,861 | $12K | |
| 84403 | <1% | 867 | $12K | |
| 73100 | <1% | 534 | $12K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 35 | $12K |
| 87522 | Neg quan hep c or qual rna | <1% | 375 | $12K |
| 82043 | <1% | 1,540 | $12K | |
| 77336 | <1% | 152 | $11K | |
| 73590 | <1% | 693 | $11K | |
| 77386 | <1% | 84 | $11K | |
| 77080 | <1% | 158 | $11K | |
| 90680 | <1% | 2,204 | $11K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 92 | $11K |
| 64484 | <1% | 416 | $10K | |
| 90715 | <1% | 210 | $10K | |
| 82784 | <1% | 1,239 | $10K | |
| 86762 | <1% | 1,058 | $10K | |
| 97162 | <1% | 166 | $10K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,442 | $9K |
| 82533 | <1% | 623 | $9K | |
| 99152 | <1% | 1,018 | $9K | |
| 84550 | <1% | 1,689 | $9K | |
| 83525 | <1% | 500 | $9K | |
| 94761 | <1% | 14,188 | $9K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 250 | $9K |
| 81003 | <1% | 8,144 | $9K | |
| 95913 | <1% | 81 | $8K | |
| 86803 | <1% | 722 | $8K | |
| 86376 | <1% | 694 | $8K | |
| 72146 | <1% | 26 | $8K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 284 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 108 | $8K |
| 76770 | <1% | 65 | $8K | |
| 84270 | <1% | 708 | $8K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 309 | $8K |
| 86787 | <1% | 846 | $8K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 23 | $8K |
| 93970 | <1% | 85 | $8K | |
| 86617 | <1% | 776 | $8K | |
| 85014 | <1% | 1,323 | $7K | |
| 95910 | <1% | 121 | $7K | |
| 99173 | <1% | 2,041 | $7K | |
| 99305 | <1% | 295 | $7K | |
| 73140 | <1% | 258 | $7K | |
| C1769 | Guide wire | <1% | 262 | $7K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 997 | $7K |
| 82950 | <1% | 843 | $7K | |
| 72040 | <1% | 237 | $7K | |
| 51798 | <1% | 687 | $6K | |
| 62321 | <1% | 13 | $6K | |
| 90658 | <1% | 1,093 | $6K | |
| 86364 | <1% | 430 | $6K | |
| 87641 | <1% | 282 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,653 | $6K |
| 87653 | <1% | 863 | $6K | |
| 52000 | <1% | 14 | $6K | |
| 99307 | <1% | 1,070 | $6K | |
| 71101 | <1% | 271 | $6K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 434 | $6K |
| 36592 | <1% | 965 | $6K | |
| 83001 | <1% | 487 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 973 | $6K |
| 87075 | <1% | 1,038 | $6K | |
| 82652 | <1% | 416 | $6K | |
| 76000 | <1% | 74 | $6K | |
| 99442 | <1% | 259 | $5K | |
| 90688 | <1% | 1,114 | $5K | |
| 87400 | <1% | 116 | $5K | |
| 95909 | <1% | 104 | $5K | |
| 95912 | <1% | 91 | $5K | |
| 87503 | <1% | 128 | $5K | |
| 85018 | <1% | 1,323 | $5K | |
| 93308 | <1% | 32 | $5K | |
| 72158 | <1% | 31 | $5K | |
| 92511 | <1% | 62 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 70 | $5K |
| 73522 | <1% | 245 | $5K | |
| 95816 | <1% | 29 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 354 | $5K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 738 | $5K |
| 74019 | <1% | 250 | $5K | |
| 94664 | <1% | 1,135 | $4K | |
| 86430 | <1% | 504 | $4K | |
| 82247 | <1% | 593 | $4K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 17 | $4K |
| 64635 | <1% | 21 | $4K | |
| 96368 | <1% | 876 | $4K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 45 | $4K |
| 82248 | <1% | 736 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,992 | $4K |
| 83615 | <1% | 446 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,723 | $4K |
| 82150 | <1% | 298 | $4K | |
| 80050 | General health panel | <1% | 128 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 203 | $3K |
| 84460 | <1% | 718 | $3K | |
| 76870 | <1% | 55 | $3K | |
| 96127 | <1% | 233 | $3K | |
| 83002 | <1% | 323 | $3K | |
| 10060 | <1% | 20 | $3K | |
| 74183 | <1% | 17 | $3K | |
| 64450 | <1% | 36 | $3K | |
| 86200 | <1% | 406 | $3K | |
| 86592 | <1% | 203 | $3K | |
| 84425 | <1% | 318 | $3K | |
| 00813 | <1% | 765 | $3K | |
| 82947 | <1% | 396 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 111 | $3K |
| 0031A | <1% | 74 | $3K | |
| 82525 | <1% | 188 | $3K | |
| 93922 | <1% | 73 | $3K | |
| 64494 | <1% | 128 | $3K | |
| A9270 | Non-covered item or service | <1% | 18,881 | $3K |
| 80143 | <1% | 1,058 | $3K | |
| 87449 | <1% | 230 | $3K | |
| 97597 | <1% | 43 | $3K | |
| 87081 | <1% | 1,530 | $3K | |
| 77002 | <1% | 357 | $3K | |
| 72170 | <1% | 177 | $3K | |
| 00840 | <1% | 424 | $3K | |
| 93018 | <1% | 282 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,671 | $2K |
| 36600 | <1% | 162 | $2K | |
| 11730 | <1% | 14 | $2K | |
| 73060 | <1% | 169 | $2K | |
| 84156 | <1% | 690 | $2K | |
| 0012A | <1% | 64 | $2K | |
| 82077 | <1% | 1,253 | $2K | |
| 82040 | <1% | 440 | $2K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 302 | $2K |
| 86317 | <1% | 118 | $2K | |
| 94060 | <1% | 73 | $2K | |
| 84450 | <1% | 360 | $2K | |
| 97035 | <1% | 34 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 33 | $2K |
| 73565 | <1% | 236 | $2K | |
| 73552 | <1% | 271 | $2K | |
| 20552 | <1% | 17 | $2K | |
| 82670 | <1% | 155 | $2K | |
| 0011A | <1% | 53 | $2K | |
| 11981 | <1% | 14 | $2K | |
| 80178 | <1% | 113 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 152 | $2K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 51 | $2K |
| 70360 | <1% | 48 | $2K | |
| 82810 | <1% | 734 | $2K | |
| 80179 | <1% | 1,014 | $2K | |
| 80069 | <1% | 149 | $2K | |
| 84145 | <1% | 437 | $2K | |
| 87481 | <1% | 128 | $2K | |
| 00811 | <1% | 160 | $2K | |
| 88112 | <1% | 261 | $2K | |
| 82803 | <1% | 98 | $2K | |
| 77280 | <1% | 13 | $2K | |
| 86665 | <1% | 148 | $2K | |
| 80164 | <1% | 114 | $1K | |
| 72052 | <1% | 43 | $1K | |
| 83993 | <1% | 112 | $1K | |
| 87563 | <1% | 144 | $1K | |
| 73070 | <1% | 77 | $1K | |
| 72114 | <1% | 85 | $1K | |
| 84630 | <1% | 154 | $1K | |
| 97166 | <1% | 45 | $1K | |
| 83520 | <1% | 159 | $1K | |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | <1% | 1,664 | $1K |
| 95251 | <1% | 205 | $1K | |
| 90716 | <1% | 120 | $1K | |
| 12002 | <1% | 14 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,631 | $1K |
| 81015 | <1% | 196 | $1K | |
| 74220 | <1% | 16 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 724 | $1K |
| 77066 | Tomosynthesis, mammo | <1% | 27 | $1K |
| 97014 | <1% | 25 | $1K | |
| 72192 | <1% | 16 | $1K | |
| 86645 | <1% | 84 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 7,931 | $1K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 275 | $1K |
| 80375 | <1% | 73 | $983.63 | |
| 0001A | <1% | 25 | $983.32 | |
| 90651 | <1% | 130 | $978.96 | |
| 86644 | <1% | 76 | $920.42 | |
| 86664 | <1% | 78 | $893.20 | |
| 84132 | <1% | 149 | $887.34 | |
| 86663 | <1% | 78 | $887.31 | |
| 84112 | <1% | 30 | $849.11 | |
| 86334 | <1% | 68 | $832.67 | |
| 83013 | <1% | 16 | $787.45 | |
| 98927 | <1% | 52 | $778.02 | |
| 73120 | <1% | 34 | $766.93 | |
| 97116 | <1% | 46 | $766.16 | |
| 64636 | <1% | 19 | $748.14 | |
| 82330 | <1% | 73 | $728.35 | |
| 84134 | <1% | 106 | $666.46 | |
| 94760 | <1% | 3,124 | $664.87 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 70 | $653.59 |
| 90619 | <1% | 64 | $595.40 | |
| 90707 | <1% | 117 | $587.84 | |
| 92523 | <1% | 13 | $587.39 | |
| 86431 | <1% | 112 | $585.00 | |
| 90700 | <1% | 116 | $572.84 | |
| 93295 | <1% | 19 | $560.76 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 20 | $557.71 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 577 | $556.90 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 31 | $555.34 |
| 96417 | <1% | 139 | $549.65 | |
| 73700 | <1% | 13 | $539.42 | |
| 82105 | <1% | 81 | $491.95 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 12 | $478.10 |
| 82948 | <1% | 496 | $471.11 | |
| 99336 | <1% | 17 | $469.69 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 20 | $451.60 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 636 | $446.55 |
| V5266 | Battery for use in hearing device | <1% | 256 | $430.79 |
| 99153 | Mod sedat endo service >5yrs | <1% | 208 | $429.43 |
| 76775 | <1% | 12 | $422.62 | |
| 30801 | <1% | 15 | $420.97 | |
| 86695 | <1% | 27 | $408.42 | |
| 86235 | <1% | 48 | $403.61 | |
| 82310 | <1% | 52 | $367.20 | |
| 84466 | <1% | 56 | $350.54 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 793 | $347.14 |
| 87045 | <1% | 23 | $334.03 | |
| 85045 | <1% | 251 | $333.95 | |
| 87324 | <1% | 25 | $332.42 | |
| 82951 | <1% | 14 | $325.64 | |
| 82140 | <1% | 57 | $323.34 | |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 26 | $322.87 |
| 86812 | <1% | 36 | $322.13 | |
| 84165 | <1% | 68 | $316.74 | |
| 90696 | <1% | 44 | $315.80 | |
| 83516 | <1% | 27 | $311.73 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 1,035 | $307.51 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 436 | $306.89 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 32 | $297.80 |
| 87512 | <1% | 12 | $289.12 | |
| 84155 | <1% | 97 | $288.43 | |
| 99217 | <1% | 12 | $287.30 | |
| 86696 | <1% | 27 | $285.95 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 409 | $285.50 |
| 90710 | <1% | 70 | $284.91 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 186 | $281.68 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 796 | $280.60 |
| 93297 | <1% | 29 | $279.16 | |
| 90685 | <1% | 75 | $279.10 | |
| 83010 | <1% | 41 | $269.43 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,689 | $259.90 |
| 82952 | <1% | 22 | $259.20 | |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 24 | $248.86 |
| 82785 | <1% | 38 | $245.37 | |
| A4223 | Infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately) | <1% | 162 | $237.14 |
| 85055 | <1% | 18 | $234.25 | |
| 00918 | <1% | 13 | $227.00 | |
| 87427 | <1% | 23 | $213.76 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 403 | $204.14 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 907 | $201.55 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 439 | $199.00 |
| 99348 | <1% | 17 | $193.07 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 308 | $192.52 |
| 76942 | <1% | 62 | $188.44 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 258 | $186.32 |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 21 | $177.98 |
| 51702 | <1% | 27 | $174.77 | |
| 99407 | <1% | 16 | $172.34 | |
| 93228 | <1% | 12 | $170.85 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,000 | $168.37 |
| 00910 | <1% | 34 | $163.59 | |
| 84480 | <1% | 18 | $159.84 | |
| 84436 | <1% | 14 | $159.60 | |
| 87205 | <1% | 61 | $151.37 | |
| 82172 | <1% | 13 | $145.91 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 235 | $132.69 |
| 86003 | <1% | 21 | $124.38 | |
| 81002 | <1% | 995 | $121.19 | |
| 00126 | <1% | 63 | $115.75 | |
| 87799 | <1% | 12 | $115.01 | |
| 90656 | <1% | 13 | $94.90 | |
| 51701 | <1% | 80 | $89.76 | |
| G0008 | Administration of influenza virus vaccine | <1% | 293 | $84.26 |
| 82010 | <1% | 62 | $82.14 | |
| 90620 | <1% | 12 | $73.05 | |
| 76937 | <1% | 65 | $69.77 | |
| 87076 | <1% | 12 | $68.03 | |
| 82365 | <1% | 58 | $66.79 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 320 | $66.34 |
| 84075 | <1% | 21 | $64.18 | |
| 88300 | <1% | 64 | $60.23 | |
| 83695 | <1% | 12 | $57.67 | |
| 90734 | <1% | 15 | $57.40 | |
| 64491 | <1% | 68 | $51.57 | |
| 93296 | <1% | 54 | $46.10 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 230 | $33.42 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 42 | $30.81 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 154 | $26.27 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 57 | $25.90 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 143 | $25.33 |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 332 | $19.73 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 38 | $14.36 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 726 | $12.75 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 150 | $10.95 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 12 | $10.13 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 203 | $9.64 |
| A6221 | Gauze, non-impregnated, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing | <1% | 22 | $9.15 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 126 | $7.66 |
| 86738 | <1% | 15 | $6.12 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 56 | $5.01 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 31 | $4.67 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 223 | $3.58 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 294 | $2.64 |
| A6448 | Light compression bandage, elastic, knitted/woven, width less than three inches, per yard | <1% | 13 | $0.97 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 145 | $0.33 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 35 | $0.24 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 23 | $0.12 |
| 91307 | <1% | 12 | $0.11 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 74 | $0.07 |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 17,511 | $0.00 |
| 3008F | 0% | 123,213 | $0.00 | |
| 3075F | 0% | 4,607 | $0.00 | |
| 1036F | 0% | 103,807 | $0.00 | |
| 3074F | 0% | 63,576 | $0.00 | |
| 3079F | 0% | 13,996 | $0.00 | |
| 3080F | 0% | 1,337 | $0.00 | |
| 3044F | 0% | 1,572 | $0.00 | |
| 95012 | 0% | 27 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 842 | $0.00 |
| 00790 | 0% | 90 | $0.00 | |
| 3017F | 0% | 98 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 166 | $0.00 |
| 0503F | 0% | 25 | $0.00 | |
| 3078F | 0% | 58,134 | $0.00 | |
| 3077F | 0% | 5,129 | $0.00 | |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 357 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 870 | $0.00 |
| G8421 | Bmi not documented and no reason is given | 0% | 990 | $0.00 |
| 83721 | 0% | 71 | $0.00 | |
| 00812 | 0% | 188 | $0.00 | |
| 4004F | 0% | 191 | $0.00 | |
| 99354 | 0% | 15 | $0.00 | |
| C1875 | Stent, coated/covered, without delivery system | 0% | 32 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 78 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 15 | $0.00 |
| 88302 | 0% | 15 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 13 | $0.00 |
| 88312 | 0% | 18 | $0.00 | |
| 88313 | 0% | 31 | $0.00 | |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWESTBROCK, PAUL (LEGAL AFFAIRS)
| Provider | Location | Paid |
|---|---|---|
| Marietta Memorial Hospital of Tyler County INC | Sistersville, WV | $2.72M |
| Marietta Memorial Hospital of Tyler County INC | Saint Marys, WV | $1.50M |
| Marietta Memorial Hospital of Tyler County INC | Sistersville, WV | $956K |
| Marietta Memorial Hospital of Tyler County INC | Middlebourne, WV | $196K |
| Marietta Memorial Hospital | Marietta, OH | $69K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.